Your browser doesn't support javascript.
loading
Efficacy and safety of camrelizumab plus transarterial chemoembolization in intermediate to advanced hepatocellular carcinoma patients: A prospective, multi-center, real-world study.
You, Ran; Xu, Qingyu; Wang, Qi; Zhang, Qingqiao; Zhou, Weizhong; Cao, Chi; Huang, Xiangzhong; Ji, Honghai; Lv, Penghua; Jiang, Hao; Lu, You; Jin, Yong; Li, Yongjun; Cheng, Long; Wang, Weidong; Xu, Hao; Zhu, Xiaoli; Yin, Guowen.
Afiliação
  • You R; Interventional Radiology Department, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research and The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China.
  • Xu Q; Interventional Radiology Department, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research and The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China.
  • Wang Q; Interventional Radiology Department, The First People's Hospital of Changzhou, Changzhou, China.
  • Zhang Q; Department of Obstetrics and Gynecology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
  • Zhou W; Interventional Radiology Department, Jiangsu Province Hospital, Nanjing, China.
  • Cao C; Interventional Radiology Department, Xuzhou Central Hospital, Xuzhou, China.
  • Huang X; Interventional Radiology Department, Jiangyin People's Hospital, Jiangyin, China.
  • Ji H; Interventional Radiology Department, Yancheng No. 1 People's Hospital, Yancheng, China.
  • Lv P; Interventional Radiology Department, The Northern Jiangsu People's Hospital, Yangzhou, China.
  • Jiang H; Interventional Radiology Department, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research and The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China.
  • Lu Y; Interventional Radiology Department, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research and The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China.
  • Jin Y; Interventional Radiology Department, The Second Affiliated Hospital of SooChow University, Suzhou, China.
  • Li Y; Interventional Radiology Department, Nantong Tumor Hospital, Nantong, China.
  • Cheng L; Interventional Radiology Department, Xuzhou Central Hospital, Xuzhou, China.
  • Wang W; Interventional Radiology Department, Wuxi People's Hospital, Wuxi, China.
  • Xu H; Department of Obstetrics and Gynecology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
  • Zhu X; Interventional Radiology Department, The First Affiliated Hospital of SooChow University, Suzhou, China.
  • Yin G; Interventional Radiology Department, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research and The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China.
Front Oncol ; 12: 816198, 2022.
Article em En | MEDLINE | ID: mdl-35982962
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Risk_factors_studies Idioma: En Revista: Front Oncol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Risk_factors_studies Idioma: En Revista: Front Oncol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China